hIL-2 NOG Mouse Model

NOD Background

  • Model #
  • Genotype
  • Nomenclature
  • 13440-F
    NOD.Cg-Prkdcscid Il2rgtm1Sug Tg(CMV-IL2)4-2Jic/JicTac
  • 13440-M
    NOD.Cg-Prkdcscid Il2rgtm1Sug Tg(CMV-IL2)4-2Jic/JicTac
  • Super immunodeficient NOG mouse expressing human IL-2 cytokine.
  • Predominant differentiation of human NK cells following human HSC engraftment, with>10-fold higher CD56+ NK cell numbers compared to the base NOG mouse.
  • Human NK cells developed in hIL-2 NOG mice express various NK receptors and produce both granzyme A and perforin upon stimulation.
  • May be an improved model for differentiation/engraftment of IL-2 dependent cells including certain blood cancers.
  • May be useful for efficacy studies involving antibody therapeutics with antibody dependent cell cytotoxcity mechanism of action.
  • Applications in research involving cancer, infectious disease, immunology, regenerative medicine and human immune system engraftment.
  • hIL-2 NOG mice produce human IL-2 in the range of 0.5-2.0 ng/mL as measured by MFI serology testing on DBS and serum in February 2023. Based on user feedback, this level appears sufficient to support engraftment of primary human T cells.
Orders by weight: Taconic cannot accept orders by weight for this model. Please note that shipments may contain animals with a larger weight variation.
What our customers say:

“Experimental Pharmacology & Oncology (EPO) GmbH uses 1st and 2nd generation NOG mice provided by Taconic for its preclinical oncology service. These mice are included in novel concepts for the development of personalized treatment options and especially suited for humanization strategies. We are very satisfied with the quality of mice, the reliability of shipment and the high level of scientific support. Further, we very much appreciate the competent and always friendly communication.”
Experimental Pharmacology & Oncology (EPO) GmbH


The CIEA NOG mouse® was developed by Mamoru Ito of the Central Institute for Experimental Animals (CIEA) in Japan. The Prkdc scid mutation was identified by Mel Bosma of the Fox Chase Cancer Center in a C.B-17 congenic mouse population. This mutation was backcrossed onto the NOD/ShiJic strain at CIEA for at least eight generations. The Il2rg targeted mutation was developed by Dr. Kazuo Sugamura of Tohoku University by targeting the gene in ES cells derived from a 129 strain. Portions of exons 7 and 8 were replaced with a neo cassette. Targeted ES cells were injected into C57BL/6 blastocysts. Resultant chimeras were backcrossed onto the C57BL/6JJic background for at least eight generations. The CIEA NOG mouse® was developed by backcrossing the C57BL/6JJic-Il2rg line to the NOD/ShiJic-Prkdc scid line for a total of eight generations. The hIL-2 NOG mouse was developed by microinjecting a transgene consisting of a DNA fragment containing human IL-2 cDNA under the control of the CMV promoter into zygotes of NOD/ShiJic-Il2rg mice. Founders were backcrossed to NOG mice to establish the hIL-2 NOG line. Taconic received stock in 2014, and the line was derived through embryo transfer.


Available now*
*Please note that advanced order placement is encouraged for male mice. Ordering 4 or more weeks prior to the desired shipping date is recommended when requesting males older than 3-weeks of age.





Initial Publication:

  • Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K, Ueyama Y, Koyanagi Y, Sugamura K, Tsuji K, Heike T, Nakahata T. (2002) NOD/SCID/γnull/c mouse: an excellent recipient mouse model for engraftment of human cells. Blood 100(9):3175-3182.
  • Fukuchi Y, Miyakawa Y, Kobayashi K, Kuramochi T, Shimamura K, Tamaoki N, Nomura T, Ueyama Y, Ito M. (1998) Cytokine dependent growth of human TF-1 leukemic cell line in human GM-CSF and IL-3 producing transgenic SCID mice. Leuk Res 22(9):837-43.
  • Katano I, Takahashi T, Ito R, Kamisako T, Mizusawa T, Ka Y, Ogura T, Suemizu H, Kawakami Y, Ito M. (2015) Predominant development of mature and functional human NK cells in a novel human IL-2-producing transgenic NOG mouse. J Immunol. 194(7):3513-25.

Nonprofit users (excluding users at nonprofit foundations which are affiliated with a for-profit entity): For internal research purposes, the CIEA NOG mouse® Conditions of Use for nonprofit users apply. If you wish to perform sponsored research or fee-for-service contract research using the CIEA NOG mouse®, please inquire for access conditions

For-profit users and users at foundations which are affiliated with for-profit entities: The CIEA NOG mouse® Conditions of Use for for-profit users apply.

Does your research require the use of neonates? Please contact us for more information on neonate access options.

The CIEA NOG mouse® is produced and distributed under license rights to the following patents and trademarks:
  • Japanese Patent No. 3,753,321
  • US Patent No. 7,145,055; 5,464,764; 5,487,992; 5,627,059; 5,631,153; 5,789,215; 6,204,061; 6,653,113; 6,689,610
    EP Patent No. 1,338,198
  • Japanese Trademark Reg. No. 4,823,423
  • US Trademark Reg. No. 3,118,040
  • EU Trademark Reg. No. 3,736,758

Improved Human T-Cell Function & Immunotherapy Modeling with hIL-2 NOG Mice

Transgenic expression of human IL2 enables TIL-mediated tumor eradication in NOG mice

NOG mice expressing human IL-2 enable TIL-mediated tumor eradication
Figure 1: Transgenic expression of human IL2 enables TIL-mediated tumor eradication in NOG mice. (a) Six hIL-2 NOG transgenic mice and three NOG mice were transplanted with luciferase labeled MM33 tumor cells. After tumor growth had been confirmed by IVIS imaging, all NOG mice, and three of the hIL-2 NOG mice, were injected with autologous REP TILs and tumor growth was measured with calipers. Shown to the right are individual mice. (b) IVIS imaging to investigate if mice are disease free. Inset, very prolonged exposure yielding mostly spark signals from static electricity. Adapted from Jespersen, et al. 2017 under Creative Commons Attribution License.

Adoptive cell transfer in hIL-2 NOG mice correlates with response in patients

Adoptive cell transfer in hIL-2 NOG mice correlates with response in patients
Figure 2: (a,b) Tumor growth curves of cells from three responders in the clinic (a: MM11, MM24 and MM05) and from two non-responders (b: MM04, MM46 and MM29) in hIL-2 NOG mice with high levels of hIL-2 treated either with PBS or TILs. Adapted from Jespersen, et al. 2017 under Creative Commons Attribution License.

Welcome! Tell us a little about yourself